Skip to main content

Advertisement

SpringerLink
Log in

CARDIOVASCULAR DISEASE

SGLT-2 inhibitors in heart failure: a new therapeutic avenue

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: A timeline of the discovery and evaluation of SGLT2 inhibitors.

References

  1. White, J. R. Clin. Diabetes 28, 5–10 (2010).

    Article  Google Scholar 

  2. Greene, S. J. et al. J Am Coll Cardiol 71, 1379–1390 (2018).

    Article  Google Scholar 

  3. Zelniker, T. A. et al. Lancet 393, 31–39 (2019).

    Article  CAS  Google Scholar 

  4. Neuen, B. L. et al. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30256-6 (2019).

    Article  PubMed  Google Scholar 

  5. Verma, S. & McMurray, J. J. V. Circulation 139, 2537–2541 (2019).

    Article  Google Scholar 

  6. McMurray, J. J. V. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911303 (2019).

    Article  PubMed  Google Scholar 

  7. Inzucchi, S. E. et al. Diabetes Care 41, 356–363 (2018).

    Article  CAS  Google Scholar 

  8. Vijayakumar, S., Vaduganathan, M. & Butler, J. Circulation 137, 1060–1073 (2018).

    Article  Google Scholar 

  9. Greene, S. J. et al. J. Am. Coll. Cardiol. 72, 351–366 (2018).

    Article  Google Scholar 

  10. Greene, S. J. et al. J. Am. Coll. Cardiol. 73, 2365–2383 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA

    Muthiah Vaduganathan

  2. Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

    Javed Butler

Authors
  1. Muthiah Vaduganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javed Butler.

Ethics declarations

Competing interests

M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. J.B. has served as a consultant to Abbott, Amgen, Array, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharma, Gilead, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave Limited and Vifor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaduganathan, M., Butler, J. SGLT-2 inhibitors in heart failure: a new therapeutic avenue. Nat Med 25, 1653–1654 (2019). https://doi.org/10.1038/s41591-019-0647-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0647-4

  • Springer Nature America, Inc.

Search

Navigation